New hope for advanced breast cancer: drug combo trial targets resistant tumors
NCT ID NCT07163481
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 29 times
Summary
This early-phase trial tests a combination of the drug sacituzumab govitecan with hormone therapy in 12 people whose HR-positive, HER2-negative metastatic breast cancer has worsened after standard CDK4/6 inhibitor treatment. The main goal is to check safety and tolerability, while also measuring how well the tumors shrink or stabilize. This is not a cure, but aims to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IV (METASTATIC) BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hunan Cancer Hospital
Changsha, Hunan, 410000, China
Conditions
Explore the condition pages connected to this study.